Control of bleeding Success in control the active variceal bleeding · acute bleeding gastric varices in people with portal hypertension
It is very uncertain whether cyanoacrylate 1 mL changes control of bleeding Success in control the active variceal bleeding compared with cyanoacrylate 0.5 mL (very low certainty).
1 finding from 1 review
Total mortality Total deaths and the end of · acute bleeding gastric varices in people with portal hypertension
It is very uncertain whether cyanoacrylate 1 mL changes total mortality Total deaths and the end of compared with cyanoacrylate 0.5 mL (very low certainty).
1 finding from 1 review
day ‐ mortality Mortality due to bleeding · acute bleeding gastric varices in people with portal hypertension
It is very uncertain whether cyanoacrylate 1 mL changes day ‐ mortality Mortality due to bleeding compared with cyanoacrylate 0.5 mL (very low certainty).
1 finding from 1 review
Failure of intervention Continuous bleeding after intervention · acute bleeding gastric varices in people with portal hypertension
It is very uncertain whether cyanoacrylate 1 mL changes failure of intervention Continuous bleeding after intervention compared with cyanoacrylate 0.5 mL (very low certainty).
1 finding from 1 review
Complications (fever) Presence of fever · acute bleeding gastric varices in people with portal hypertension
It is very uncertain whether cyanoacrylate 1 mL changes complications (fever) Presence of fever compared with cyanoacrylate 0.5 mL (very low certainty).
1 finding from 1 review
Clinical cure: syndromic approach · sexually active adults
Macrolide (erythromycin) showed no clear difference in clinical cure: syndromic approach compared with any other macrolide (low certainty).
1 finding from 1 review
Clinical cure: aetiological approach · sexually active adults
Macrolide (erythromycin) showed no clear difference in clinical cure: aetiological approach compared with any other macrolide (low certainty).
1 finding from 1 review
Minor adverse events · sexually active adults
It is very uncertain whether macrolide (erythromycin) changes minor adverse events compared with any other macrolide (very low certainty).
1 finding from 1 review
Intervention not reported
Intracranial pressure (mmHg) · adults presenting with elevated intracranial pressure secondary to a traumatic brain injury
1 finding from 1 review
Intervention not reported
Anatomic success (i.e. patent lacrimal passage after a period of at least six months after operation) · People with nasolacrimal duct obstruction
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Decompressive craniectomy or corticectomy performed to reduce intracranial pressure during the surgery · people with intracranial aneurysm
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical remission · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus may leads to higher clinical remission compared with placebo (low certainty).
1 finding from 1 review
Clinical improvement · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in clinical improvement compared with beclometasone (low certainty).
1 finding from 1 review
Serious adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in serious adverse events compared with beclometasone (low certainty).
1 finding from 1 review
Total adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in total adverse events compared with beclometasone (low certainty).
1 finding from 1 review
Clinical improvement · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus may leads to higher clinical improvement compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
It is very uncertain whether tacrolimus changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Total adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in total adverse events compared with placebo (low certainty).
1 finding from 1 review
Clinical remission · adults with refractory, moderate‐to‐severe ulcerative colitis
It is very uncertain whether tacrolimus changes clinical remission compared with ciclosporin (very low certainty).
1 finding from 1 review
Clinical improvement · adults with refractory, moderate‐to‐severe ulcerative colitis
It is very uncertain whether tacrolimus changes clinical improvement compared with ciclosporin (very low certainty).
1 finding from 1 review